Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2012, Article ID 626417, 8 pages
http://dx.doi.org/10.1155/2012/626417
Research Article

Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis

1A.I. Virtanen Institute, University of Eastern Finland, 70211 Kuopio, Finland
2Biocenter Kuopio, University of Eastern Finland, 70211 Kuopio, Finland
3School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland
4National Institute for Health and Welfare, Public Health Genomics Unit, Biomedicum Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
5Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
6Department of Pediatrics, Kuopio University Hospital, 70211 Kuopio, Finland

Received 22 February 2012; Revised 11 April 2012; Accepted 18 April 2012

Academic Editor: Jia You Fang

Copyright © 2012 Tuulia Huhtala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Santavuori, “Neuronal ceroid-lipofuscinoses in childhood,” Brain and Development, vol. 10, no. 2, pp. 80–83, 1988. View at Google Scholar · View at Scopus
  2. J. Vesa, E. Hellsten, L. A. Verkruyse et al., “Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis,” Nature, vol. 376, no. 6541, pp. 584–587, 1995. View at Google Scholar · View at Scopus
  3. R. Riikonen, S. L. Vanhanen, J. Tyynelä, P. Santavuori, and U. Turpeinen, “CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis,” Neurology, vol. 54, no. 9, pp. 1828–1832, 2000. View at Google Scholar · View at Scopus
  4. A. Jalanko, J. Vesa, T. Manninen et al., “Mice with Ppt1Δex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons,” Neurobiology of Disease, vol. 18, no. 1, pp. 226–241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Macauley, D. F. Wozniak, C. Kielar, Y. Tan, J. D. Cooper, and M. S. Sands, “Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse,” Experimental Neurology, vol. 217, no. 1, pp. 124–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Jalanko and T. Braulke, “Neuronal ceroid lipofuscinoses,” Biochimica et Biophysica Acta, vol. 1793, no. 4, pp. 697–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Ahtiainen, J. Kolikova, A. L. Mutka et al., “Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction,” Neurobiology of Disease, vol. 28, no. 1, pp. 52–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Ahtiainen, K. Luiro, M. Kauppi, J. Tyynelä, O. Kopra, and A. Jalanko, “Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing,” Experimental Cell Research, vol. 312, no. 9, pp. 1540–1553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. von Schantz, J. Saharinen, O. Kopra et al., “Brain gene expression profiles of Cln1 and Cln5 deficient mice unravels common molecular pathways underlying neuronal degeneration in NCL diseases,” BMC Genomics, vol. 9, article 146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Kielar, L. Maddox, E. Bible et al., “Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis,” Neurobiology of Disease, vol. 25, no. 1, pp. 150–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Torres-Aleman, M. Villalba, and M. P. Nieto-Bona, “Insulin-like growth factor-I modulation of cerebellar cell populations is developmentally stage-dependent and mediated by specific intracellular pathways,” Neuroscience, vol. 83, no. 2, pp. 321–334, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. G. A. Werther, V. Russo, N. Baker, and G. Butler, “The role of the insulin-like growth factor system in the developing brain,” Hormone Research, vol. 49, no. 1, supplement, pp. 37–40, 1998. View at Google Scholar · View at Scopus
  13. J. L. Trejo, E. Carro, E. Garcia-Galloway, and I. Torres-Aleman, “Role of insulin-like growth factor I signaling in neurodegenerative diseases,” Journal of Molecular Medicine, vol. 82, no. 3, pp. 156–162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Riikonen, “Neurotrophic factors in the pathogenesis of neurological disorders with mental retardation in children,” Current Pediatric Reviews, vol. 3, no. 3, pp. 207–213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. D. Beck, L. Powell-Braxton, H. R. Widmer, J. Valverde, and F. Hefti, “Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons,” Neuron, vol. 14, no. 4, pp. 717–730, 1995. View at Google Scholar · View at Scopus
  16. E. J. Schoenle, G. K. Haselbacher, and J. Briner, “Elevated concentration of IGF II in brain tissue from an infant with macrencephaly,” Journal of Pediatrics, vol. 108, no. 5, pp. 737–740, 1986. View at Google Scholar · View at Scopus
  17. J. Zhong, L. Zhao, Y. Du, G. Wei, W. G. Yao, and W. H. Lee, “Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats,” Neurological Research, vol. 31, no. 5, pp. 483–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. C. Apfel, J. C. Arezzo, M. E. Lewis, and J. A. Kessler, “The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice,” Annals of the New York Academy of Sciences, vol. 692, pp. 243–245, 1993. View at Google Scholar · View at Scopus
  19. M. J. Carson, R. R. Behringer, R. L. Brinster, and F. A. McMorris, “Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice,” Neuron, vol. 10, no. 4, pp. 729–740, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Guan, “Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury,” Recent Patents on CNS Drug Discovery, vol. 3, no. 2, pp. 112–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Fernandez, A. Gonzalez De La Vega, and I. Torres-Aleman, “Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 3, pp. 1253–1258, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Hellstrom, C. Perruzzi, M. Ju et al., “Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5804–5808, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. S. B. Lupien, E. J. Bluhm, and D. N. Ishii, “Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats,” Journal of Neuroscience Research, vol. 74, no. 4, pp. 512–523, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. A. E. Lovett-Racke, P. Bittner, A. H. Cross, J. A. Carlino, and M. K. Racke, “Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3),” Journal of Clinical Investigation, vol. 101, no. 8, pp. 1797–1804, 1998. View at Google Scholar · View at Scopus
  25. D. L. Yao, X. Liu, L. D. Hudson, and H. D. F. Webster, “Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis,” Life Sciences, vol. 58, no. 16, pp. 1301–1306, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. J. D. Cooper, A. Messer, J. Chua-Couzens, and W. C. Mobley, “Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin- like growth factor-1 treatment,” Journal of Neuroscience, vol. 19, no. 7, pp. 2556–2567, 1999. View at Google Scholar · View at Scopus
  27. S. Ranta, Y. Zhang, B. Ross et al., “The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8,” Nature Genetics, vol. 23, no. 2, pp. 233–236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. R. C. Baxter, “Insulin-like growth factor binding proteins in the human circulation: a review,” Hormone Research, vol. 42, no. 4-5, pp. 140–144, 1994. View at Google Scholar · View at Scopus
  29. C. A. Conover, M. Ronk, F. Lombana, and D. R. Powell, “Structural and biological characterization of bovine insulin-like growth factor binding protein-3,” Endocrinology, vol. 127, no. 6, pp. 2795–2803, 1990. View at Google Scholar · View at Scopus
  30. R. Rajah, A. Khare, P. D. K. Lee, and P. Cohen, “Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells,” Journal of Endocrinology, vol. 163, no. 3, pp. 487–494, 1999. View at Google Scholar · View at Scopus
  31. J. Dupont and M. Holzenberger, “Biology of insulin-like growth factors in development,” Birth Defects Research Part C, vol. 69, no. 4, pp. 257–271, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. S. C. Bayliss, R. Heald, D. I. Fletcher, and L. D. Buckberry, “The culture of mammalian cells on nanostructured silicon,” Advanced Materials, vol. 11, pp. 318–321, 1999. View at Google Scholar
  33. J. Salonen, A. M. Kaukonen, J. Hirvonen, and V. P. Lehto, “Mesoporous silicon in drug delivery applications,” Journal of Pharmaceutical Sciences, vol. 97, no. 2, pp. 632–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Limnell, J. Riikonen, J. Salonen et al., “Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles,” International Journal of Pharmaceutics, vol. 343, no. 1-2, pp. 141–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Kilpeläinen, J. Mönkäre, M. A. Vlasova et al., “Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 77, no. 1, pp. 20–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Salonen, M. Björkqvist, E. Laine, and L. Niinistö, “Stabilization of porous silicon surface by thermal decomposition of acetylene,” Applied Surface Science, vol. 225, no. 1–4, pp. 389–394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Joo, “Current aspects of the development of the blood-brain barrier,” International Journal of Developmental Neuroscience, vol. 5, no. 5-6, pp. 369–372, 1987. View at Google Scholar · View at Scopus
  38. N. R. Saunders, G. W. Knott, and K. M. Dziegielewska, “Barriers in the immature brain,” Cellular and Molecular Neurobiology, vol. 20, no. 1, pp. 29–40, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. R. C. Wiggins, “Myelin development and nutritional insufficiency.,” Brain Research, vol. 257, no. 2, pp. 151–175, 1982. View at Google Scholar · View at Scopus
  40. Z. Laron, S. Anin, Y. Klipper-Aurbach, and B. Klinger, “Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism,” The Lancet, vol. 339, no. 8804, pp. 1258–1261, 1992. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Laron, “The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 12, pp. 4397–4404, 1999. View at Google Scholar · View at Scopus
  42. Z. Laron, “Insulin-like growth factor-I (IGF-I): safety and efficacy,” Pediatric Endocrinology Reviews, vol. 2, no. 1, pp. 78–85, 2004. View at Google Scholar · View at Scopus
  43. H. Vestergaard, M. Rossen, S. A. Urhammer, J. Müller, and O. Pedersen, “Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus,” European Journal of Endocrinology, vol. 136, no. 5, pp. 475–482, 1997. View at Google Scholar · View at Scopus
  44. J. Hatton, R. P. Rapp, K. A. Kudsk et al., “Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a phase II safety and efficacy trial,” Journal of Neurosurgery, vol. 86, no. 5, pp. 779–786, 1997. View at Google Scholar · View at Scopus
  45. W. Pan and A. J. Kastin, “Interactions of IGF-1 with the blood-brain barrier in vivo and in situ,” Neuroendocrinology, vol. 72, no. 3, pp. 171–178, 2000. View at Google Scholar · View at Scopus
  46. Z. Laron, “Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity),” Pediatric Endocrinology Reviews, vol. 5, no. 3, pp. 766–771, 2008. View at Google Scholar · View at Scopus
  47. L. K. Midyett, A. D. Rogol, Q. L. Van Meter, J. Frane, and G. M. Bright, “Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 611–619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Devesa, N. Casteleiro, C. Rodicio, N. López, and P. Reimunde, “Growth hormone deficiency and cerebral palsy,” Journal of Therapeutics and Clinical Risk Management, vol. 6, pp. 413–418, 2010. View at Google Scholar
  49. Y. Yu, A. J. Kastin, and W. Pan, “Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier,” Endocrinology, vol. 147, no. 6, pp. 2611–2615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. B. F. Sun, H. Kobayashi, N. Le et al., “Effects of insulinlike growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice,” Journal of Nuclear Medicine, vol. 41, no. 2, pp. 318–326, 2000. View at Google Scholar · View at Scopus
  51. B. F. Sun, H. Kobayashi, N. Le et al., “Biodistribution of 125I-labeled des(1–3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism,” Cancer Research, vol. 57, no. 13, pp. 2754–2759, 1997. View at Google Scholar · View at Scopus
  52. T. Tanaka, L. S. Mangala, P. E. Vivas-Mejia et al., “Sustained small interfering RNA delivery by mesoporous silicon particles,” Cancer Research, vol. 70, no. 9, pp. 3687–3696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Rytkönen, R. Miettinen, M. Kasalainen, V.-P. Lehto, J. Salonen, and A. Närvänen, “Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes,” Journal of Nanomaterials, In press.
  54. L. M. Bimbo, M. Sarparanta, H. A. Santos et al., “Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats,” ACS Nano, vol. 4, no. 6, pp. 3023–3032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Li, L. Quigley, D. L. Yao et al., “Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects,” Journal of Neuropathology and Experimental Neurology, vol. 57, no. 5, pp. 426–438, 1998. View at Google Scholar · View at Scopus